Case Study: Xspray Pharma
Solving insolubility. Read Xspray Pharma's drug development case study.
Xspray Pharma is a drug delivery company based in Stockholm, Sweden that concentrates on solving a common problem in the pharmaceutical industry today, that of variable bioavailability due to poor solubility in gastric fluid, pH-dependent absorption, and food interactions. Protein kinase inhibitors (PKIs) are used in the treatment of cancer and inflammation, but food interactions are a common problem with this class of drugs. Swedish drug delivery company Xspray Pharma has used its Hybrid Nanoparticle (HyNap™) technology to improve the bioavailability of the PKI nilotinib, reducing the required dose and significantly lowering the food interaction of the drug compared with the marketed product.
Working closely with Quotient Sciences', Xspray Pharma took advantage of our integrated approach in their Phase I study. They were able to go back to the lab, change the dose, transfer the new formulation to the manufacturing facilities, and be back testing in the clinic, all in a very short space of time. This approach made a significant difference to the speed of the results that they gained and reduced their program timelines.
Download a copy of our case study with Xspray Pharma today and find out how we can accelerate your drug development timelines.
